Last reviewed · How we verify
CHS-388
At a glance
| Generic name | CHS-388 |
|---|---|
| Also known as | Casdozokitug |
| Sponsor | Coherus Oncology, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma (PHASE2)
- Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |